Clinical trials in Saronno – page 43

2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Saronno at a glance

2 862

clinical trials

Research sites1

Quick filters

2 862 trials in Saronno

Open in trial search

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ocrelizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Vulval cancer

Recruiting

Study of pembrolizumab and lenvatinib treatment for patients with vulvar cancer

Registered drugNo placebo

Study of pembrolizumab and lenvatinib treatment for patients with vulvar cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Lenvatinib
Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Contact Research Centre

Adenocarcinoma pancreas+2

Recruiting

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Novartis Pharma AG

Contact Research Centre

Colitis ulcerative+1

Recruiting

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Vedolizumab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Acute myocardial infarction

Recruiting

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:ECRI-trials B.V.

Contact Research Centre

Acarodermatitis

Recruiting

Comparing effectiveness of topical permethrin, oral ivermectin, and their combination for treating patients with confirmed scabies infection

Registered drugNo placebo

Comparing effectiveness of topical permethrin, oral ivermectin, and their combination for treating patients with confirmed scabies infection

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ivermectin
Sponsor:Giuliani S.p.A.

Contact Research Centre

Bipolar I disorder+1

Recruiting

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Trospium Chloride
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Study of Mosunetuzumab Treatment in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

InvestigationalNo placebo

Study of Mosunetuzumab Treatment in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Mosunetuzumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Myelodysplastic syndrome

Recruiting

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Nucresiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Saronno

What the registry says about research in the country

01 Respiratory Oncology

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.

MET deregulation therapy assessment
Second-line combination treatments
EGFR mutation targeting

Research emphasizes personalized treatment strategies for advanced and metastatic disease states.

02 Women's Oncology

Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.

Endocrine-responsive breast cancer treatment
Ovarian cancer maintenance therapy
BRCA wild-type cancer management

Investigations aim to optimize treatment sequences and improve patient outcomes.

03 Specialized Oncology & Cardiology

Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.

Metastatic renal cancer therapy
Atrial fibrillation management
Targeted combination therapies

Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.

Back to Italy All countries